Opportunity

Federal Register #SR-CBOE-2026-072

SEC Notice: Proposed Increase to Cboe Exchange Options Regulatory Fee (ORF)

Buyer

Securities and Exchange Commission

Posted

August 31, 2026

Respond By

September 21, 2026

Identifier

SR-CBOE-2026-072

NAICS

523210

This notice from the Securities and Exchange Commission (SEC) announces a proposed rule change by Cboe Exchange, Inc. regarding the Options Regulatory Fee (ORF). - Government Buyer: - Securities and Exchange Commission (SEC), Division of Trading and Markets - Cboe Exchange, Inc. is the submitting entity - OEM/Vendor: - Cboe Exchange, Inc. (the only OEM/vendor mentioned) - Products/Services Requested: - Options Regulatory Fee (ORF) - Fee increase from $0.0023 to $0.01248 per contract side for customer options transactions executed on the Exchange - Supports regulatory supervision, investigations, examinations, and enforcement activities - No physical products or traditional services are being procured; this is a fee adjustment - Unique/Notable Requirements: - Fee applies only to customer range options transactions executed on Cboe Exchange - Methodology aims to equitably allocate regulatory costs and avoid overlapping fees across exchanges - Ongoing semi-annual monitoring to ensure fees align with regulatory costs; future adjustments possible - Public comments invited on the proposed changes - No procurement of goods or services; this is a regulatory fee change notice

Description

The Securities and Exchange Commission issued a notice regarding a proposed rule change by Cboe Exchange, Inc. to amend the Options Regulatory Fee (ORF). The proposal includes increasing the ORF from $0.0023 to $0.01248 per contract side for options transactions that occur on the Exchange and clear in the customer range, effective July 1, 2026. The rule change aims to recover a material portion of the Exchange's regulatory costs related to supervision and regulation of customer options business. The notice invites public comments and provides details on the fee structure and regulatory rationale.

View original listing